These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33712484)

  • 21. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
    Kaldırım HE; Yazgan S
    Int Ophthalmol; 2018 Aug; 38(4):1549-1558. PubMed ID: 28646440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
    JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
    Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
    Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
    Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
    JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.
    Adedokun L; Burke C
    Adv Ther; 2016 Jan; 33(1):116-28. PubMed ID: 26747252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept.
    Spooner K; Hong T; Bahrami B; Chang A
    Acta Ophthalmol; 2019 Feb; 97(1):15-23. PubMed ID: 30251325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.
    Ip MS; Oden NL; Scott IU; VanVeldhuisen PC; Blodi BA; Ghuman T; Baker CW;
    JAMA Ophthalmol; 2019 Mar; 137(3):281-287. PubMed ID: 30589922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.
    Ciulla T; Pollack JS; Williams DF
    Br J Ophthalmol; 2021 Dec; 105(12):1696-1704. PubMed ID: 33055088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.
    Gabrielle PH; Nguyen V; Creuzot-Garcher C; Arnold JJ; Mehta H; Duran MA; Bougamha W; Carreño E; Viola F; Squirrell D; Barthelmes D; Gillies M
    Retina; 2022 Jun; 42(6):1085-1094. PubMed ID: 35174799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal Aflibercept versus Ranibizumab for Diabetic Macular Edema in a Taiwanese Health Service Setting.
    Tsai MJ; Cheng CK
    Semin Ophthalmol; 2021 Apr; 36(3):132-138. PubMed ID: 33661709
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
    Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
    Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion.
    Yucel OE; Birinci H; Sullu Y
    Int Ophthalmol; 2019 Apr; 39(4):891-901. PubMed ID: 29550932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study.
    O'Day R; Ali N; Lim LL; Sandhu S; Chau T; Wickremasinghe S
    BMC Ophthalmol; 2020 Feb; 20(1):69. PubMed ID: 32093666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
    JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry.
    Bhandari S; Nguyen V; Arnold J; Young S; Banerjee G; Gillies M; Barthelmes D
    Ophthalmology; 2020 Mar; 127(3):369-376. PubMed ID: 31757494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.